Answers are grounded in this paper and cite their sources.
Observational study reveals elevated Interleukin-6 and depleted sgp130 in severe COVID-19 respiratory distress, suggesting cytokine receptor imbalance drives fatal hyper-inflammation.
In December 2019 a novel RNA beta-corona virus, highly contagious, was recognized to be the cause of previously pneumonia cases of unknown origin.The virus is phylo-genetically similar to SARS-CoV and has been called SARS-CoV-2 (COVID-19).Most common is the emerging of a strong dys-regulation of the immune response, that leads to disease severity in COVID-19 patients.There are a lot of suggestions indicating that mortality, strong in critically ill patients, might be correlated with virally driven hyper-inflammation, due to a cytokine storm.Interleukin-6 (IL-6) plays an important role in cytokine release syndrome and elevated IL-6 level is a hallmark inflammatory signature seen in serum of patients with severe COVID-19 acute respiratory distress (ARDS).We analyzed blood inflammation indicators, IL-6 and its receptor complex and TNF-α, in order to demonstrate that cytokines unbalanced systems can be considered an early tool to identify critical patients and to predict their poor prognosis.Our study was conducted on N=23 critically patients with confirmed COVID-19 and admitted in Intensive Care Unit (ICU) from March 10 to April 30 due to severe respiratory failure.Serum levels of IL-6, sIL-6R, sgp130 and TNF-α were determined using CLIA and ELISA as immunoassay.Our data shown that not all patients have higher values in serum of sIL-6R agonist receptor, compared to the controls.For this reason we have stratified all patients in two different group (1 and 2).We observed that in GROUP 1 as well as in GROUP 2 the IL-6 and TNF-α serum levels are significantly increased in respect to the controls.Despite, sgp130 antagonist receptor levels are significantly decreased in all patients.Further studies are required to better investigate the role of IL-6 and its soluble receptor complex during COVID-19 disease and to evaluate the possible involvement of other cytokines also in response to different pharmacological treatment.
No takes yet. Share an insight, caveat, or question.
Spigna et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: